Collegium Pharmaceutical Inc (NASDAQ:COLL) has been assigned an average rating of “Buy” from the ten research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $31.80.
COLL has been the subject of a number of analyst reports. Janney Montgomery Scott set a $26.00 target price on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, February 6th. Piper Jaffray Companies set a $33.00 target price on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, January 23rd. Zacks Investment Research cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Jefferies Group lifted their target price on shares of Collegium Pharmaceutical to $27.00 and gave the company a “buy” rating in a research note on Tuesday, December 5th. Finally, TheStreet upgraded shares of Collegium Pharmaceutical from a “d+” rating to a “c” rating in a research note on Wednesday, March 7th.
In other news, insider Alison B. Fleming sold 6,928 shares of the business’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $19.07, for a total value of $132,116.96. Following the completion of the sale, the insider now directly owns 32,651 shares in the company, valued at $622,654.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Michael Thomas Heffernan sold 20,000 shares of the business’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $25.01, for a total transaction of $500,200.00. Following the completion of the sale, the chairman now owns 535,395 shares of the company’s stock, valued at $13,390,228.95. The disclosure for this sale can be found here. Insiders sold 46,928 shares of company stock valued at $1,082,317 over the last 90 days. 25.76% of the stock is owned by corporate insiders.
Institutional investors have recently modified their holdings of the company. Voya Investment Management LLC acquired a new stake in shares of Collegium Pharmaceutical in the second quarter worth $125,000. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Collegium Pharmaceutical by 87.5% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock worth $138,000 after buying an additional 3,500 shares during the last quarter. Nationwide Fund Advisors lifted its stake in shares of Collegium Pharmaceutical by 27.8% in the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after buying an additional 2,802 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Collegium Pharmaceutical in the fourth quarter worth $176,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Collegium Pharmaceutical in the third quarter worth $192,000. Institutional investors and hedge funds own 87.60% of the company’s stock.
Shares of Collegium Pharmaceutical (NASDAQ COLL) opened at $27.59 on Wednesday. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $29.90.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.02. The firm had revenue of $10.79 million during the quarter, compared to analysts’ expectations of $9.88 million. Collegium Pharmaceutical had a negative net margin of 262.91% and a negative return on equity of 73.00%. The firm’s revenue for the quarter was up 728.4% compared to the same quarter last year. research analysts expect that Collegium Pharmaceutical will post -0.71 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/03/14/collegium-pharmaceutical-inc-coll-receives-average-rating-of-buy-from-brokerages.html.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.